BIONTECH SE SPON. ADRS 1
Commented by André Will-Laudien on April 12th, 2021 | 08:30 CEST
BioNTech, Formycon, Psybio Therapeutics: A chance for normality?
It is a matter of course: The desire for normality! Things have not been normal over the last 12 months, which everyone is now feeling. Our society has had a lot to shoulder since the turn of the millennium. The extreme increase in radicalism, the emergence of dangerous dictators and incompetent politicians, the polarization of beliefs, the explosive development of wealth in shares and real estate owners with simultaneous global impoverishment, the excessive indebtedness of the states, and now, a worldwide pandemic of unimagined proportions. It takes a good deal of imagination to believe in a "normalization" and then a more philosophical question quickly arises: What does an economic reality with and after the pandemic look like?
Read
Commented by Nico Popp on March 23rd, 2021 | 14:00 CET
BioNTech, Marble Financial, Disney: Innovations that pay off
The stock market is where the future is traded. Groundbreaking innovations can completely change this future and provide investors with high returns from the very beginning. Examples include all investors who took an early stake in shares of Amazon or Alphabet. There are also currently a whole series of shares that stand for innovation. We present three stocks.
Read
Commented by Nico Popp on March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.
Read
Commented by Nico Popp on March 9th, 2021 | 07:15 CET
BYD, BioNTech, Kleos Space: A new trend starts here
If you want to be successful on the stock market, you have to back those shares with prospects. Although an intact upward trend suggests that a story will be well received on the market, the fall height also increases with the price. Investors have recently had to experience this pain, especially with shares in the field of electromobility or hydrogen. Even vaccine hopefuls such as BioNTech have lost ground. Let us show you how the trend stocks are faring and which sector is only at the beginning of its trend!
Read
Commented by André Will-Laudien on March 2nd, 2021 | 11:15 CET
Q&M Dental, Pfizer, BioNTech, Teva: Watch out for these pharma picks!
The COVID pandemic has permanent surprises in store, which strongly influence our daily life. The province of Tyrol was sealed off entirely 2 weeks ago. The Czech Republic is being helped out with vaccine doses because the incidence figures are going through the roof. In Germany, hairdressers and DIY stores have been allowed to open again. Gradually, everyday life is returning to normal, but it will probably take some time before we regain the quality of life of the pre-Corona years. Let's take a closer look at various business models in the healthcare industry to get a feel for what's next.
Read
Commented by Nico Popp on February 4th, 2021 | 08:15 CET
BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown
If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.
Read
Commented by André Will-Laudien on December 1st, 2020 | 09:54 CET
Desert Gold, BioNTech, Vodafone - Healthier, Cleaner, Gold!
Asian stocks have recently faltered near their record highs, but the Nikkei, in particular, has experienced a grand rally of 15% in the last 4 weeks. Yesterday 30.11. is a popular settlement day for fund managers around the globe because from this date on you only have 1 month to clean the portfolio from unwanted components. In simple terms, stocks which ran poorly all year are likely to be sold and stocks that everyone's talking about and have performed well so far, tend to be topped up again. Among asset management experts, these measures are called "window dressing", i.e., perfecting the design of the viewing rooms in the form of a portfolio listing.
On the market as a whole, investors seem to be developing the view that the economic recovery will gain momentum next year, and this is driving some to liquidate their gold holdings - intended as a security investment - rather than to sell them. On the technical front, support for gold remains intact at around USD 1,750 to USD 1,770 an ounce. Silver continues to see massive interest near the psychological level of USD 22-23, the Technical Analysis tells us. Whether we can take this as a given at the end of the year remains to be seen; the pressure on precious metals prices is currently high.
Read
Commented by Stefan Feulner on November 25th, 2020 | 11:15 CET
Moderna, Triumph Gold, BioNTech - bet on winners!
Gold has not made it out - for the time being. Due to the decision of the Americans pro Joe Biden and the very successful developments regarding a vaccine against the coronavirus, the precious yellow metal went downhill for the time being. The correction may well continue a little further. However, in the past, these setbacks were lucrative with anti-cyclical entry opportunities. Therefore, one should use the time now to take a closer look at promising gold mines.
Read
Commented by Stefan Feulner on November 20th, 2020 | 11:20 CET
BioNTech, Saturn Oil & Gas, Moderna - these stocks will explode!
Now it's all happening at once with the news in the race against the Corona pandemic. According to BioNTech and its US competitor Moderna, first deliveries of the vaccine are scheduled for the end of this year and the start of 2021. The first step towards normality, even though the head of BioNTech, Ugur Sahin, does not expect a normal social life until the end of 2021 at the earliest. Then, if everything goes smoothly, badly shaken industries should experience an unprecedented renaissance, and their share prices should take off.
Read
Commented by André Will-Laudien on November 13th, 2020 | 12:40 CET
Pfizer, BioNTech, Desert Gold - inoculate portfolios with gold!
After only three days, disillusionment already! The winners of yesterday are the losers of today. Since Monday's vaccination rocket, the markets have been hanging around up there, looking to see if any more buyers have left the sickbed of the last bear market. Unfortunately, no, the case is rather that airlines are, on average, down 5% again and a battered TUI is looking for further state aid which pushes the price back towards 4 euros. The problematic week began as the Dow rose by 4% to a new record high, and yields on ten-year government bonds shot up by almost 17% in a single day as investors relinquished security. Oil prices rose by 8% as people now believe that the stalled economy is coming back to life.
Meanwhile, the US dollar index rose by about 60 basis points, while even some exotic currencies with higher beta jumped too. Of course, some gold and silver enthusiasts wonder if a vaccine is enough to kill both the Covid-19 virus and the bull market in precious metals as gold and silver lost between 5 and 9%. However, if you look at the markets today, the chances are that smart money, in particular, will start to buy the dips in the precious metals.
Read